Market Overview

Bristol-Myers Squibb Says Orencia Approved by EU

Share:
Related BMY
Most Of Credit Suisse's Top Investment Ideas For 2016...In One Place
Is Big Pharma Hinting At A SMID-Cap Biotech Rally?
Intercept Pharma Spikes On Report That It's Exploring A Sale (Investor's Business Daily)

Bristol-Myers Squibb announced today that the European Commission has granted marketing authorisation for the subcutaneous formulation of ORENCIA ® (abatacept), in combination with methotrexate (MTX), for the treatment of adults with moderate to severe active rheumatoid arthritis (RA).

Posted-In: News FDA

 

Related Articles (BMY)

View Comments and Join the Discussion!

Get Benzinga's Newsletters